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INTERLEUKIN (IL)-15 has emerged as a key regulator of
both  natural  killer  (NK)  cell  differentiation  and
activation.  The  aim  of  the  present  study  was  to
investigate the expansion of the population of cells
expressing killer-cell immunoglobulin-like receptors
(CD158a and CD158b) in human peripheral lympho-
cytes by treatment with IL-15. One million peripheral
lymphocytes  were  cultured  in  RPMI1640  medium
alone or in medium containing IL-2 at 100U/ml or IL-
15  at  0.1,  1.0,  or  10.0ng/ml  for  48h.  After  each
incubation,  we  assessed the  natural  killing  activity
and  the  population  of  CD16+CD158a+/b+ cells  and
CD8+CD158a+/b+ cells. IL-15 increased the NK activity
and expanded the populations of CD16+CD158a+/b+
cells and CD8+CD158a+/b+ cells. These actions were
dose dependent, and the effects of IL-15 at 1.0ng/ml
were close to those of IL-2 at 100U/ml. These findings
suggest  that  IL-15  induces the effector functions of
resting NK  cells  throughout  the body, and thereby
plays  a  critical  role  in  the  activation  of  tissue-
associated immune responses.
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Introduction
Since  the  molecular  cloning  of  natural  killer  (NK)
receptors  was  achieved  in  1995,1–3 it  has  subse-
quently been shown that these receptors, which are
now called killer cell immunoglobulin-like receptors
(KIRs), transmit positive and/or negative signals.4,5 It
is now widely accepted that the expression of KIRs is
involved  in  the  cytolytic  function  of  NK  cells,  as
demonstrated  by  a  number  of  studies  focusing  on
these  receptors.6,7 Analysis  of  KIR  expression  has
contributed to revealing the regulation and function
of NK cell activation.
Interleukin  (IL)-15  was  discovered  in  1994  and
shown to have the potential to enhance cell-mediated
immune  responses  to  intracellular  pathogens  and
tumors.8,9 IL-15 shares no homology with IL-2, but IL-
15  shares  many  of  the  biologic  activities  of  IL-2,
including  induction of the proliferation of phytohe-
magglutinin-stimulated  normal  peripheral  blood
mononuclear cells (PBMC), NK cells, B cells, and T
cells, and generation of allogenic cytotoxic T lympho-
cytes in vitro.8–13
Although  IL-2  and  IL-15  are  lymphocyte  growth
factors  with  overlapping  functions  in  immune
responses, the cells that produce IL-15 are different
from  those  that  produce  IL-2.  IL-2  is  produced  by
activated T cells, while in contrast IL-15 is produced
by  epithelial  cells  and  macrophages,  which  range
over the whole body.8 Thus, it is considered that IL-
15  maintains T  cells,  diminishes  the  occurrence of
malignant  tumors  and  defends  against  microbial
infections, and that these actions are partly  due to
the enhancement of the function of NK cells by IL-
15.  Indeed,  IL-15  is  an  essential  regulator  of  the
differentiation of NK cells from stem cells,14–16 and
moreover IL-15 can stimulate or augment the activa-
tion of mature human NK cells.17 However, little is
known about the effects of IL-15 on the expression
of  NK  receptors,  which  are  involved  in  NK  cell
regulation.
The  aim  of  the  present  study  was  to  assess
the  effect  of  IL-15  on  the  expression  of  KIRs  on
mature  NK  cells  (CD16+)  and  CD8+ T  cells  to
clarify  the  mechanism  of  NK  cell  regulation  by
IL-15.
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Reagents
Fluorescein  isothiocyanate  (FITC)-conjugated  anti-
human  CD8, FITC-anti-human CD16,  phycoerythrin
(PE)-conjugated  anti-human  CD158a  and  PE-conju-
gated  anti-human  CD158b  were  purchased  from
Immunotech  (Marseille,  France).  Recombinant
human IL-2 was obtained from Pharmabiotechnology
(Hannover, Germany). Recombinant human IL-15 was
purchased  from  Strathmann  Biotech  (Hamburg,
Germany).
Cells
PBMC obtained from 10 healthy subjects were sepa-
rated from heparinized blood by Lymphoprep (Nye-
gaard,  Oslo,  Norway)  gradient  cenfugation.18 Each
PBMC sample was incubated in a culture dish in  a
humidified 5% CO2/95% air atmosphere at 37°C for
60min. After the incubation, non-adherent cells were
collected  and  washed  twice  in  phosphate-buffered
saline.
Cell culture
One  million  cells  were  cultured  in  RPMI  1640
medium  supplemented  with  10%  fetal  calf  serum
(Biological Industries, Israel) in tissue culture dishes
(Becton  Dickinson,  Franklin,  NJ,  USA).  The  cell
cultures were incubated in medium only or medium
supplemented with IL-2 at 100U/ml or IL-15 at 0.1,
1.0,  or 10.0ng/ml  in  a humidified  5% CO2/95% air
atmosphere at 37°C for 48h. After each incubation,
cells were collected and their surface antigens were
analyzed using flow cytometry (Epics XL; Beckman
Coulter, France). Each experiment was carried out in
duplicate.
Cell phenotype
Surface  phenotyping  was  carried  out  using  a  two-
color immunofluorescence staining technique, with
isotype-specific  mouse  anti-human  antibody  conju-
gated with either FITC or PE.19 Each sample of stained
cells was suspended in 0.5ml of phosphate-buffered
saline and analyzed by flow cytometry. Lymphocyte
subsets were identified by gating analysis, and fluores-
cence profiles were obtained for 10,000 cells of each
sample. Negative controls for each experiment were
performed with FITC- and PE-labeled mouse immuno-
globulin G.
NK cytolytic activity
NK activity was assessed against K562, a myelogenous
leukemia  cell  line,  in  a  3-h  51Cr-release  assay  as
described previously. The effector cells were mixed
with labeled target cells at various cell concentrations
to  give  an  effector-to-target  ratio  of  20:1  or  10:1.
Duplicate samples were prepared for each ratio. The
supernatants were withdrawn after a 4-h incubation
period, and the 51Cr released from lysed target cells
was quantitated in a gamma counter (Packard Instru-
ment Co., Boston, MA, USA). Incubation of target cells
with medium or saponin (7mg/ml) and ethylenedia-
mine tetraacetic acid (0.1mg/ml) was used to deter-
mine spontaneous and maximal release, respectively.
The  percent  cytotoxicity  was  calculated  by  the
formula: (cpm of effector cells – cpm of spontaneous
release)/(cpm  of  maximal  release – cpm  of  sponta-
neous release) ´ 100.
Statistical analysis
Data  are  expressed  as  mean  (standard  deviation)
values. All data were collected in a computer database
and  analyzed  using  the  StatView-J  4.02  program
(Abacus Concept, Berkeley, CA, USA). The Wilcoxon
signed-rank test was performed for each set of data for
NK  activity  and  surface  antigen  expression.  For  all
statistical tests,  differences  were  regarded as  statis-
tically significant at p<0.05.
Results
Enhancement of NK cytolytic activity by IL-15
To confirm the ability of IL-15 to elevate the natural
killing  activity,  we  measured  the  NK  activity  after
incubation (48h) with IL-15 (concentration, 0.1, 1.0,
or 10.0ng/ml). The results are presented in Table 1. At
0.1ng/ml of IL-15, the NK activity was significantly
increased compared with medium alone. The increase
of NK cytolytic activity by treatment with IL-15 was
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Table 1. Natural killing activity (%) after treatment (48h) with IL-2 or IL-15
Effector/target Medium alone IL-2
100U/ml
IL-15
0.1ng/ml 1.0ng/ml 10.0ng/ml
10/1 6.5 ± 3.2 25.8 ± 15.6* 11.6 ± 4.2* 24.3 ± 6.9* 46.3 ± 8.5*#
20/1 12.2 ± 4.8 36.2 ± 16.4* 20.3 ± 6.4* 34.7 ± 5.7* 64.5 ± 14.4*#
*p<0.05 versus medium alone, # p<0.05 versus IL-2 100U/ml.dose dependent from 0.1 to 10ng/ml. The effect of
1.0ng/ml of IL-15 was similar to that of 100U/ml of IL-
2, and 10ng/ml of IL-15 significantly elevated the NK
activity compared with 100U/ml of IL-2.
Expansion of the CD16
+CD158a/b
+ cell
population by IL-15
The signals from KIRs play a crucial role in NK cell
regulation, and therefore we investigated the popula-
tions of CD158a-positive and CD158b-positive cells.
IL-15  at  1.0ng/ml  expanded  the  population  of
CD16+CD158a+ cells significantly, and this effect was
nearly to equal to that of 100U/ml of IL-2 (Fig. 1). The
expansion of CD16+CD158a+ cells by treatment with
IL-15 was dose dependent from 0.1 to 10ng/ml. IL-15
also  expanded  the  population  of  CD16+CD158b+
cells,  but  the  effect  of  10ng/ml  of  IL-15  was  not
different from that of 1.0ng/ml of IL-15 or 100U/ml of
IL-2 (Fig. 1). The populations of CD8+CD158a+ cells
and CD8+CD158b+ cells were expanded similarly to
those  of  the  respective  CD16+ cells  by  IL-15.  In
Regulation of KIRs by IL-15
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FIG. 1. The expansion of cells expressing KIRs in human peripheral lymphocytes by IL-15 or IL-2. Peripheral lymphocytes
were cultured in medium alone or medium supplemented with IL-2 at 100U/ml or with IL-15 at 0.1, 1.0, or 10.0ng/ml for
48h.  After  each  incubation,  the  populations  of  CD16
+CD158a
+/b
+ and  CD8
+CD158a
+/b
+ cells  were  measured  using  flow
cytometry. (A): CD16
+CD158a
+ cells. Both 1.0 and 10.0ng/ml of IL-15 significantly expanded this population. These effects of
IL-15  were  dose  dependent  from  0.1  to  10.0ng/ml  in  vitro.  (B):  CD16
+CD158b
+ cells.  Both  1.0  and  10.0ng/ml  of  IL-15
significantly expanded this population although there was no difference between the effects of 1.0 and 10.0ng/ml of IL-15.
(C): CD8
+CD158a
+ cells. Both 1.0 and 10.0ng/ml of IL-15 significantly expand this population, and the effect of 1.0ng/ml of
IL-15 was nearly equal to  that of  100U/ml of IL-2. (D):  CD8
+CD158b
+ cells.  Both 1.0 and 10.0ng/ml of  IL-15 significantly
expanded this population, although there was no difference between the effects of 1.0 and 10.0ng/ml IL-15. *p<0.05 versus
medium alone # p<0.05 versus 100U/ml of IL-2contrast,  the  total  populations  of  CD8+ cells  and
CD16+ cells were not changed by treatment with IL-
15 (data not shown).
In addition, we further analyzed the change in the
expression per cell of KIRs in response to IL-15. The
representative data was shown in Fig. 2. The CD158b
molecule on each lymphocyte were upregulated.
The change of the percentage of CD158a
+/b
+
cells in CD8
+ or CD16
+ cells by IL-15
IL-15  treatment  at  each  concentration  tested
increased  the  percentage  of  CD158a+/b+ cells  in
CD16+ cells. IL-15 at 10ng/ml significantly increased
the  percentage  of  such  cells  in  comparison  with
medium  alone.  The  percentage  of  CD158a-  and
CD158b-expressing  cells  among  CD8+ cells  was
also  increased by  treatment with 10ng/ml  of  IL-15
(Table 2).
Discussion
IL-15 has been reported to exert proliferative effects
on T-cell lines and to share many biologic properties
with  IL-2.8,9,11 At  optimal  concentrations,  IL-15
rapidly induces memory (CD45RO+) CD4+ and CD8+
T cells and naive (CD45RO–) CD8+ T cells to express
the CD69 activation marker, followed by proliferation.
However, IL-15 appears to have no chemokinetic or
chemotactic activity  on  human  monocytes  or  neu-
trophils.20,21 In the present study, the population of
CD8+ cells was not expanded by the treatment with
IL-15. Instead, the population of activated T lympho-
cytes probably increased.
As  for  NK  cells,  the  proliferation,  survival,  and
effector functions of resting NK cells are induced by
exogeneous  IL-15.9,17 In  vitro,  IL-15  induces  the
cytotoxic activity of NK cells as well as T cells.15,22
Our data also demonstrated that IL-15 enhances NK
activity. Although the degree of its ability to enhance
the  NK activity  varies  depending  on  the  report,  it
appeared to be more effective than IL-2 in the present
study. The biological functions of IL-15 are similar to
T. Kogure et al.
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FIG.  2.  The  change  of  the  KIRs  expression  per  cell  in
response  to  IL-15.  Representative  data  using  PE-labeled
CD158b  was  shown.  Upper  panel,  medium  alone;  lower
panel,  medium  with  10ng/ml  of  IL-15.  The  population  of
CD158b-positive cell was 8.7% in medium alone, and 9.7%
under  the  condition  in  medium  with  10ng/ml  of  IL-15.
Especially, the intensity of PE was higher in medium with
10ng/ml of IL-15 than in medium alone. These phenomena
indicated that the CD158b molecule on each lymphocyte was
upregulated.
Table 2. The percentage of CD158a
+/b
+ cells in CD16
+ or CD8
+ cells after treatment (48h) of IL-2 and IL-15
Effector/target Medium alone IL-2
100U/ml
IL-15
0.1ng/ml 1.0ng/ml 10.0ng/ml
CD16
+ cells
CD16
+CD158a
+ cells 8.7 ± 7.0 13.3 ± 8.0 9.8 ± 4.4 12.6 ± 8.6 20.6 ± 11.2*
CD16
+CD158b
+ cells 25.3 ± 6.1 28.4 ± 7.2 26.6 ± 6.3 29.6 ± 6.8 32.5 ± 9.3*
CD8
+ cells
CD8
+CD158a
+ cells 4.3 ± 4.6 7.5 ± 7.3 5.9 ± 6.0 7.0 ± 7.8 11.2 ± 7.4*
CD8
+CD158b
+ cells 10.3 ± 2.2 12.1 ± 3.3 11.0 ± 3.1 11.7 ± 3.5 13.2 ± 4.2*
*p<0.05 versus medium alone.those of IL-2, but they have some different character-
istics.  First,  when  the  cytotoxicity  of  T  cells  is
enhanced  by  IL-2  or  IL-15,  IL-15  promotes  their
survival while IL-2 predisposes activated T cells to die
by apoptosis.23 Second, IL-2 and IL-15 are produced
by different cell types, namely epithelial cells, mono-
cytes or macrophages produce IL-15, while in  con-
trast, IL-2 is produced by activated T cells. Therefore,
it  is  suggested  that IL-15  has  a  general  role  in  the
activation  of  innate  and  tissue-associated  immune
responses.
It is now widely accepted that NK cells recognize
and  lyse  target  cells  through  the  interplay  of  two
families  of  receptors.24–26 One  family  consists  of
killer-cell  activating  receptors  such  as  CD6927 and
2B4,28 and the other consists of KIRs. The activating
signal  can  be  over-ridden  by  a  dominant-negative
signal  from  a  KIR when  the KIR  interacts with  its
ligand on the target cell, although activating recep-
tors, when occupied, trigger lysis of the target cell
being recognized. Recently, it has been reported that
KIR downregulation on NK cells is associated with
the  downregulation  of  activating  receptors,29 and
there is a biphasic response of NK cells expressing
KIRs, in which high expression of CD158b transmits
inhibitory  signals  to  NK  cells  whereas low  expres-
sion  transmits  activating  signals.30 These facts  indi-
cate that signals from NK receptors play important
roles  in  NK  cell  regulation. Therefore,  we  further
analyzed  the  effects  of  IL-15  on  the  expression  of
KIRs recognized by CD158a/b. Our findings demon-
strated that IL-15 expanded the populations of both
CD16+CD158a+/b+ cells and CD8+CD158a+/b+ cells.
In addition, the expression per cell of these KIRs in
response to IL-15  was upregulated. The expansions
of CD16+CD158a+ or CD8+CD158b+ cells were dose
dependent from 0.1 to 10ng/ml, as was the increase
of NK cytolytic activity by treatment with IL-15. In
contrast, while the expansions of the CD158b+ cell
population was dose dependent from 0.1 to 1.0ng/
ml, there was no significant difference between the
effect  of  10ng/ml  and  that  of  1.0ng/ml.  We  con-
sidered that further expansion of CD158b+ cells did
not  occur  despite  the  increase  of  NK  activity  by
10ng/ml compared with 1.0ng/ml because the NK
activity  is  dependent  on  several  signals  from  NK
receptors.  However,  it  is  difficult  to  explain  the
difference  between  the  responses  of  the  CD158a
and  CD158b  molecules. The  possible  shared  func-
tions of the CD158a and CD158b molecules are still
not  known,  although  it  is  well  known  that  their
ligands are different.
To investigate the effects of IL-15 on the expression
of KIRs on CD8+ cells and CD16+ cells, we further
calculated the percentage of CD8+ and CD16+ cells
expressing  KIRs. There was  no  difference  between
the percentage of such cells among CD8+ cells and
CD16+ cells,  suggesting  that  IL-15  upregulated  the
expression of KIRs on both CD8+ and CD16+ cells, as
did IL-2.
In conclusion, we demonstrated the effects of IL-15
on peripheral lymphocytes in human. IL-15 increased
the  NK  activity,  and  expanded  the  population  of
CD16+CD158a+/b+ and CD8+CD158a+/b+ cells, sug-
gesting  that IL-15  induces the  effecter functions  of
resting  NK  cells  throughout  the  whole  body  and
thereby plays a critical role in the activation of tissue-
associated immune responses.
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